Abstract: |
Axillary lymph node dissection (ALND), once considered standard of care for all patients with invasive breast cancer, is now obsolete in patients with histologically negative sentinel lymph nodes (SLNs). Alternatives to ALND in patients with histologically positive SLNs are available after the ACOSOG Z0011 and AMAROS trials demonstrated no difference in locoregional recurrence, dis-ease-free survival, or overall survival between SLN biopsy alone (ACOSOG Z0011) or with axillary radiotherapy (AMAROS) and ALND in women with clinical T1-2 invasive breast cancer and 1–2 positive SLNs treated with mul-timodality therapy, offering the opportunity to reduce the morbidity of treatment. In contrast, the MA.20 and EORTC 22922-10925 studies suggest that similar patient populations benefit from ALND and comprehensive nodal irradiation. Here, we will discuss the contemporary surgical management of clinically node-negative breast cancer patients with metastases in the SLNs. © Springer Science + Business Media New York 2015. |